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ABSTRACT Idiopathic pulmonary fibrosis (IPF) is one of the most common forms of interstitial lung
disease presenting in persons 50 years and older. Through a comprehensive review of available studies, we
aimed to assess health-related quality of life (HRQoL) of people living with IPF and the instruments used
in this assessment. Searches were conducted up to May, 2020. Quality appraisal and data extraction were
performed using pre-designed forms. Narrative synthesis approach was used to report results of the
systematic review and a random effects model was used for the meta-analysis. A leave-one-out sensitivity
analysis was performed, and a trim and fill method was used to assess publication bias.
The review included 134 studies. The most used instruments to measure HRQoL were St George’s
Respiratory Questionnaire (SGRQ), Short Form 36 (SF36) and EuroQoL (EQ5D). Standardised mean
scores (95% confidence interval) for these instruments were as follows: SGRQ total score: 44.72 (42.21–
47.22); SF36 physical component score (PCS): 37.00 (34.74–39.26) SF36 mental component score (MCS):
50.18 (48.41–51.95); King’s Brief Interstitial Lung Disease questionnaire total score: 58.38 (55.26–61.51);
and EQ5D utility: 0.73 (0.68–0.79). Analysis of standardised means for both SGRQ and SF36
demonstrated worse scores in physical health domains as compared to mental health domains.
This systematic review confirms that IPF negatively affected HRQoL, mostly impacting the physical
health domains. This study also demonstrated that a diverse number of instruments are used to evaluate
HRQoL. In view of this diversity, a standardised approach to measurement of HRQoL for IPF is
important to ensure that comparisons made are reliable.
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Idiopathic pulmonary fibrosis (IPF) is one of the most common interstitial lung diseases in the elderly
[1, 2]. It is characterised by progressive fibrosis and destruction of lung tissue, which leads to variably
rapid decreases in lung function and eventual respiratory failure and death [3]. Although the disease
course may vary, evidence suggests the median survival time for IPF from diagnosis is 2–4 years [4, 5].
People with IPF usually experience increasingly debilitating symptoms including cough, dyspnoea, fatigue
and weight loss [6], all of which have an impact on their daily life. Treatment options for the disease are
quite limited and only two recently introduced drugs are known to slow disease progression but not cure
the disease [7].
Given this combination of symptom burden, poor prognosis and limited treatment options, it is important
to ascertain the impact that the disease has on quality of life. How the disease impacts an individual’s
quality of life or the health-related quality of life (HRQoL) is determined by several factors, including the
disease course, the individual’s perceptions of their disease and their coping mechanisms [8].
Consequently, a holistic approach to the management and care of people with IPF and the evaluation of
new therapies should take into consideration how these therapies improve HRQoL in addition to
improving clinical outcomes.
To improve the HRQoL in people with the disease we must first ascertain the best methods to measure it
accurately and reliably. To date, research in this field has been limited [9]. In addition, there is still some
debate about the appropriate instruments to measure HRQoL specifically in IPF [9, 10]. Several
instruments have been used to measure the HRQoL in IPF, including generic instruments such as the
St. George’s Respiratory Questionnaire (SGRQ), and Short Form-36 (SF36). With novel anti-fibrotic drugs
now available and active research ongoing into the development of other drugs and treatment modalities,
it is important to establish a standardised approach for the measurement of HRQoL as an outcome of
treatment. This will assist in harmonising comparisons made across populations and intervention studies.
In this current study, we conducted a comprehensive review of existing literature to evaluate studies that
have examined HRQoL in IPF. We sought to determine how IPF affected HRQoL, and the measurement
tools used in this assessment. Moreover, this study expands on previously conducted reviews on HRQoL
[11, 12] as many studies have been published over the last 3 years.
Methods
This review was done in accordance with the Preferred Reporting Items for Systematic Reviews and
Meta-Analysis Protocols and registered to the international prospective register of systematic reviews,
PROSPERO (CRD42018111292). This protocol was subsequently updated to include a meta-analysis.
Search strategy
Searches were conducted up to May 2020, in MEDLINE, EMBASE, PSYCHINFO, SCOPUS, the Centre for
Reviews and Dissemination (CRD), Database of Abstracts of Reviews of Effects (DARE), National Health
Service Economic Evaluation Database (NHS EED) and the Cost-Effectiveness Analysis Registry (CEA
Registry). Search strategies for the databases are included in the supplementary material (supplementary
material S3). Hand searches were conducted using reference lists for the retrieved studies and previous
systematic reviews [11, 12] to identify additional studies.
Study selection
Studies were included if they were intervention or observational studies; if they included and reported
measurements on quality of life; and if the reporting language was English, French, Spanish or German.
Inclusion and exclusion criteria are available in supplementary material S2.
Endnote referencing software [13] was used to catalogue all searches and to omit duplicates. The studies
that remained after duplicate removal were screened by two reviewers simultaneously using Covidence
online software [14] in two phases: title/abstract and then full text. This was completed by two reviewers
simultaneously (I.A. Cox, B. de Graaff ). A third reviewer (E.H. Walters) was consulted if there were
conflicts in the study selection.
Data extraction and management
Data from the selected studies were extracted into predesigned Excel spreadsheets. The following variables
were collected: authors, country of study, publication year, study type, clinical standards for diagnosis,
quality-of-life instrument used and quality-of-life scores reported (mean and standard deviation), number
of participants with IPF, proportion of males, mean age and forced vital capacity (FVC) as % predicted.
For studies that involved an intervention, the quality-of-life measurements taken before intervention
commencement were used.
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Quality assessment
Quality assessment of the studies was conducted using a combination of criteria adopted from previous
studies [6, 12, 15–17]. These evaluated the IPF case definition, demographic and clinical characteristics of
the IPF participants, clinical diagnosis standards, the HRQoL measurement instrument selection and the
study endpoints (supplementary material S4). A points-based system was used to calculate the total score
for each study, which was then represented as a percentage of the highest attainable score. Studies were
then classified into low (<50%), medium (50–75%) and high (>75%) quality based on the percentage
calculated.
Data analysis
A descriptive approach including use of figures and tables was used for reporting the results of the
systematic review. Pooled means were calculated for age and FVC % pred. The mean age was then
categorised into age groups (supplementary material S5-1) and FVC % pred. was used to categorise disease
severity based on the level pulmonary function impairment [18–20] (supplementary material S5-2). In
studies for which standard deviations were not reported for quality-of-life scores, standard errors and
sample size were used to calculate the missing data [21]. In studies for which medians were reported for
quality-of-life scores, means and standard deviations were calculated using methods by HOZO et al. [22]
and LUO et al. [23].
The R software [24] and the “metafor” package [25] was used to conduct the meta-analysis. When
multiple papers were reporting on the same study, the paper with the largest sample size was used in the
meta-analysis. The between study variability was considered using the random effects model. The I2
statistic was used to evaluate heterogeneity and inconsistency across the studies [26, 27] and the Cochrane
Handbook was used to classify the levels of heterogeneity [28]. To further evaluate the cause of
heterogeneity, a subgroup analysis was conducted in which two or more studies were available, for disease
severity, age group and study quality. Sensitivity analyses were conducted using two methodologies. The
first method omitted one study at a time [28, 29]. The second method arranged the studies by sample size
in ascending order (smallest to largest), then starting with the three smallest studies, one study was added
at a time, to assess the influence on the mean [30]. Finally, the “trim and fill” method was used to assess
publication bias [28, 29].
Results
Initial searches identified a total of 3578 abstracts from databases and 15 studies from reference list hand
searches. After the screening process, a total of 134 studies conformed with the inclusion criteria and 97
were included in the meta-analyses. The Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) flow diagram (figure 1) summarises the selection process. All reasons for
exclusion of full text studies are explained in the supplementary material S6. All studies included in the
meta-analyses are reported in supplementary material S7.
General characteristics of all studies included
The number of studies published has increased substantially in the past 5 years (figure 2). Approximately
57% of all the studies included were published between 2015 and 2020 while the remaining 43% of the
articles were published between 2000 and 2014 (figure 2). Most studies were from Europe (33%), North
America (23%) and Asia (20%). Multi-country clinical trials accounted for 18% of all studies and the USA
(20%) and Japan (13%) were the most studied individual countries. Detailed information on individual
studies can be found in table 1.
Participant characteristics
The participants for most studies were predominantly male, excepting for five studies [31–37]. A high
proportion of studies (92%) had participants whose mean age was ⩾60 years with the exception of 10
studies [33, 34, 38–45]. The remaining studies did not report the age of the participants. Only a small
number of studies reported on ethnicity most of whom were Caucasian (table 1 and supplementary
material S8).
Clinical diagnosis and staging
Clinical diagnosis in most studies (87%) was based on one of the following international consensus
standards: American Thoracic Society (ATS)/European Respiratory Society (ERS) or ATS/ERS/Japanese
Respiratory Society ( JRS)/Latin American Thoracic Society (ALAT), dependent on the year the study was
conducted. In cases where the international guidelines were not used, one study used the Chinese Thoracic
Society (CTS) standards [46], another used ICD-10 coding [47], and one relied on participants’
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self-reported diagnosis [48]. The criteria used for the remaining studies was not defined [32–34, 36, 39, 40,
42, 43, 46–57].
With reference to disease severity [18–20], 51% of studies reported on participants with moderate disease
severity, 37% were on participants with mild disease while only 4% of studies included participants with
severe disease [33, 40–42, 55] (table 1 and supplementary material S8).
Study quality
Supplementary material S4 provides a summary of the study quality criteria used and how the studies
performed against each individual criterion. Most studies were of medium quality, 28% were of high
quality and 6% low quality.
HRQoL measurement instruments
A diverse number of instruments were used in the studies, with predominance of the use of the generic
form of the SGRQ either used singularly or combined with other instruments (60%). The SGRQ is a
disease-specific instrument for obstructive lung disease with three domains: activity, impact and
symptoms; and a total score. The total score for each domain is depicted as a percentage of the overall
impairment on a scale of 0–100%, with 0% and 100% being the best and worst possible health status
respectively [58].
The SF36 was the second most used instrument (30%). The SF36 is a generic instrument used to measure
HRQoL across several disease conditions. It has eight domains: physical functioning, physical role, general
health, bodily pain, vitality, social functioning, emotional role and mental health; and two summary
scores: physical component score (PCS) and mental component score (MCS). All of these are measured on
a scale from 0–100, where lower scores indicate a worse health status [59].
The EQ5D was not used individually in any study but was used in combination with other assessment
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FIGURE 1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow chart illustrating study selection process.
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EQ5D-3 level and the EQ5D-5 level. This generic multi-attribute instrument is used for measuring
HRQoL over several disease conditions. It reports two measures: the visual analogue scale (VAS) which
ranges from 0–100 where a higher score reflects better HRQoL; and, secondly, the health state utility value
which is used in economic evaluations. The utility score is reported on a scale between 0 and 1, where 1
represents the best quality of life and 0 represents death. Negative scores are possible, indicating states
considered worse than death [60].
12 studies made use of the ILD-specific King’s Brief Interstitial Lung Disease questionnaire (KBILD) [36,
54, 56, 61–69]. This instrument measures three domains: psychological, breathlessness/activities and chest
symptoms. The scores range from 0–100, where 100 represents the best score [36].
A limited number of studies used disease-specific (IPF) instruments, although many of the studies were
conducted after their development in 2010. Of these, five studies [52, 70–73] used the disease-specific




60 studies were included in the meta-analysis. The pooled mean scores (95% CI) were as follows: activity,
57.13 (48.40–65.87), symptoms, 50.82 (48.32–53.32); impact, 37.00 (34.41–39.68); and total, 44.72 (42.21–
47.22). Domain scores reflecting physical wellness (activity and symptoms) were generally worse than
those reflecting emotional wellness (impact).
Both disease severity and age group were observed to have an influence on the SGRQ score. The pooled
mean score worsened with increasing disease severity. For age group, there was no consistent pattern, but
the worst scores were recorded in the youngest age group (figure 3a). The subgroup analysis on quality of
the studies demonstrated that there was a minimal difference between the total scores for medium- and
high-quality studies. Low-quality studies had a much higher total score, 57.94, signifying a lower quality of
life; however, only four studies were included in this analysis and the degree of certainty was low as
demonstrated by the wide confidence intervals.
SF36
32 studies were included in the analysis. Pooled mean scores (95% CI) for the PCS and MCS were 37.00
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FIGURE 2 Number of included studies by publication year.
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TABLE 1 Summary of all studies included in the review
















De Vries et al. [77] Netherlands 2000 Cohort study NR NR SGRQ
WHOQOL
10 40 61.1 79.6
Martinez et al. [43] Brazil 2000 Cross-sectional study NR NR SF36 34 59 52.3 62.4
Clark et al. [78] UK 2001 Prospective observational study ATS/ERS 2000 SF36 50 66 67.7 80.9
De Vries et al. [31] Netherlands 2001 Cross-sectional study ATS/ERS 2000 WHOQOL 41 37 63.5 NR
Baddini et al. [38] Brazil 2002 Cohort study ATS/ERS 2000 SF36 30 60 58.6 61.9
Jastrzebski et al. [41] Poland 2005 Cross-sectional study ATS/ERS 2000 SF36 16 69 48.3 44.0
Nishiyama et al. [79] Japan 2005 Prospective observational study ATS/ERS 2000 SGRQ 41 85 64.0 76.6
Tomioka et al. [80] Japan 2005 RCT ATS/ERS 2000 SF36 22 NR 70.0 72.5
Tzanakis et al. [81] Sweden 2005 Cross-sectional study ATS/ERS 2000 SGRQ 25 80 66.0 68.8
Antoniou et al. [82] Greece 2006 RCT ATS/ERS 2000 SGRQ 50 84 66.9 71.4
Tomioka et al. [83] Japan 2007 Cross-sectional and longitudinal study ATS/ERS 2000 SF36 46 70 69.9 71.0
Zimmermann et al. [84] Brazil 2007 Cross-sectional study ATS/ERS 2000 SGRQ
SF36
20 NR 61.5 70.4
Feltrim et al. [39] Brazil 2008 Cross-sectional cohort study NR NR SGRQ 7 57 54.1 NR
King et al. [85] Multi-country 2008 RCT (BUILD-1) ATS/ERS 2002 SGRQ
SF36
154 73 65.2 67.8
Krishnan et al. [86] USA 2008 Cross-sectional study ATS/ERS 2000 SF36 39 54 67.7 68.9
Nishiyama et al. [87] Japan 2008 RCT ATS/ERS 2000 SGRQ 28 75 66.2 67.5
Peng et al. [88] China 2008 Cross-sectional and longitudinal study ATS/ERS 2000 SGRQ 68 64.0 66.0
Raghu et al. [89] USA 2008 RCT ATS/ERS 2000 SGRQ
SF36
87 68 65.2 63.9
Han et al. [90] USA 2009 Cross-sectional study ATS/ERS 2000 SGRQ
SF12
221 67 63.0 62.9
IPF Clinical Research
Network et al. [91]
USA 2010 RCT (STEP-IPF) ATS/ERS 2000 SGRQ
EQ5D
SF36
180 83 69.0 56.8
Jastrzebski et al. [42] Poland 2010 Cross-sectional study NR NR SGRQ
SF36
30 80 52.2 41.2
Key et al. [92] UK 2010 Cross-sectional study ATS/ERS 2002 LCQ NR 74 70.8 78.5
Lindell et al. [93] USA 2010 Mixed method intervention study ATS/ERS 2000 SF36 21 76 66.2 NR
Lutogniewska et al.
[51]
Poland 2010 NR NR NR SGRQ
SF36
30 NR NR NR
Ozalevli et al. [94] Turkey 2010 Prospective observational study ATS/ERS 2000 SF36 15 67 62.8 71.6
Raghu et al. [95] Multi-country 2010 RCT (BUILD-1) ATS/ERS 2000 SGRQ 154 73 65.2 67.8
Swigris et al. [74] USA 2010 Cohort study ATS/ERS 2000 ATAQ-IPF 95 82 69.3 66.0
Swigris et al. [76] USA 2010 RCT (BUILD-1) ATS/ERS 2000 SGRQ
SF36
100 73 65.1 66.97
du Bois et al. [96] Multi-country 2011 RCT ATS/ERS 2000 SGRQ 822 71 66.0 72.5
Elfferich et al. [49] Netherlands 2011 Cross-sectional study other NR WHOQOL 49 63 63.1 82.9
Jones et al. [97] UK 2011 Case control study ATS/ERS 2002 LCQ NR 63 72.0 80.4
King et al. [98] Multi-country 2011 RCT (BUILD-3) ATS/ERS 2000 SF36
EQ5D










































Kozu et al. [99] Japan 2011 Prospective non-randomised open trial ATS/ERS 2000 SF36 45 82 67.5 68.6
Kozu et al. [100] Japan 2011 Prospective non-randomised, and
uncontrolled study
ATS/ERS 2000 SF36 65 71 67.5 65.3
Mishra et al. [101] India 2011 RCT ATS/ERS 2002 SGRQ NR 100 70.7 61.4
Rammaert et al. [102] France 2011 Prospective observational study ATS/ERS 2000 SGRQ
SF36
NR 62 67.1 67.0
Swigris et al. [103] USA 2011 Prospective observational study ATS/ERS 2000 SF36 21 86 71.5 73.0
Verma et al. [45] Canada 2011 Cross-sectional study ATS/ERS 2000 SGRQ
SF36
137 66 59.4 61.7
Horton et al. [50] USA 2012 RCT other NR SGRQ
CQLQ
23 78 67.6 70.4
Nishiyama et al. [104] Japan 2012 Retrospective cohort study ATS/ERS 2000 SGRQ 87 89 66.3 75.0





145 73 67.0 58.8




155 75 68.4 70.7
Shulgina et al. [107] UK 2012 RCT ATS/ERS 2000 SGRQ
EQ5D
181 72 71.6 70.7
Swigris et al. [108] USA 2012 RCT (STEP-IPF) ATS/ERS 2005 SGRQ
SF36
180 83 69.0 56.8




20 75 67.6 70.4
Mermigkis et al. [110] Greece 2013 Prospective cohort study ATS/ERS/JRS/
ALAT
2011 SF36 23 78 68.2 76.2
Tzouvelekis et al. [111] Greece 2013 Non-randomised Clinical Trial ATS/ERS/JRS/
ALAT
2011 SGRQ 14 86 64.4 74.2
Alhamad [112] Saudi Arabia 2014 Retrospective cohort study ATS/ERS/JRS/
ALAT
2011 SF36 58 57 62.9 65.2
Gaunaurd et al. [71] USA 2014 RCT ATS/ERS/JRS/
ALAT
2011 SGRQI 21 68.6 60.5
IPF Clinical Research
Network et al. [113]





264 78 67.7 72.8
Kozu et al. [114] Japan 2014 Prospective cross-sectional study ATS/ERS/JRS/
ALAT
2011 SF36 65 71 67.5 65.3
Lubin et al. [115] USA 2014 Cohort study ATS/ERS 2000 SF36 102 75 70.0 70.0
Morsi et al. [33] Egypt 2014 Cross-sectional study NR NR SGRQ 36 22 53.0 46.3
Richeldi et al. [116] Multi-country 2014 RCT (INPULSIS-1, INPULSIS-2) ATS/ERS 2000 SGRQ 1061 79 66.8 79.6
Rifaat et al. [34] Egypt 2014 Prospective observational study ATS/ERS/JRS/
ALAT
2011 SGRQ 30 27 54.4 51.9
Vainshelboim et al.
[117]
Israel 2014 RCT ATS/ERS/JRS/
ALAT










































Bors et al. [118] USA 2015 Prospective, cross-sectional study ATS/ERS/JRS/
ALAT
2011 SF36 46 63 64.6 61.7
Huang et al. [119] China 2015 RCT ATS/ERS/JRS/
ALAT
2011 SGRQ 76 93 60.3 77.3
Mermigkis et al. [120] Greece 2015 Prospective cohort study ATS/ERS/JRS/
ALAT
2011 SF36 55 NR 70.3 NR
Nathan et al. [121] Multi-country 2015 RCT (CAPACITY) ATS/ERS 2000 SGRQ 338 73 66.5 74.7
Raghu et al. [122] Multi-country 2015 RCT ATS/ERS 2000 SGRQ 126 80 65.0 67.2
Vainshelboim et al.
[123]
Israel 2015 RCT ATS/ERS/JRS/
ALAT
2011 SGRQ 28 66 67.3 68.2





77 59 76.4 84.3




41 75 67.1 75.4
Costabel et al. [125] Multi-country 2016 RCT (INPULSIS-1, INPULSIS-2) ATS/ERS 2000 SGRQ 1061 79 66.8 79.6
Ferrara et al. [61] Sweden 2016 Cross-sectional study ATS/ERS/JRS/
ALAT
2011 KBILD 71 70 68.3 77.5
Hopkins et al. [47] Canada 2016 Retrospective population-based study ICD NR HUI2 8295 54 NR NR
Kolb et al. [126] Multi-country 2016 RCT (INPULSIS-1, INPULSIS-2) ATS/ERS 2000 SGRQ 1081 78 65.5 78.1
Kotecha et al. [127] UK 2016 Cohort study ATS/ERS/JRS/
ALAT
2011 SGRQ 75 58 76.4 83.6
Richeldi et al. [128] Multi-country 2016 RCT (TOMORROW-1, INPULSIS-1,
INPULSIS-2)
ATS/ERS 2000 SGRQ 1231 79 66.5 79.7
Taniguchi et al. [129] Multi-country 2016 RCT (INPULSIS-1, INPULSIS-2) ATS/ERS 2000 SGRQ 322 80 66.0 81.2
Yount et al. [48] USA 2016 Prospective cohort study Patient referred NR ATAQ-IPF
PROMIS
220 70 61.0 NR
Yu et al. [46] China 2016 RCT CTS NR SGRQ NR NR NR NR
Arizono et al. [130] Japan 2017 Prospective observational study ATS/ERS 2002 SGRQ 22 64 70.5 72.2
Azuma et al. [131] Japan 2017 RCT (INPULSIS-1, INPULSIS-2) ATS/ERS 2000 SGRQ 126 81 68.3 81.9




24 63 67.6 73.0
Cheng et al. [132] Canada 2017 Prospective cohort study ATS/ERS/JRS/
ALAT
2011 SGRQ 77 69 68.7 73.2
Collard et al. [133] Multi-country 2017 RCT (INPULSIS-1, INPULSIS-2) ATS/ERS 2000 SGRQ 1061 79 66.8 79.6
Dowman et al. [52] Australia 2017 RCT NR NR SGRQI 61 67 71.4 75.9
Furukawa et al. [134] Japan 2017 Retrospective cohort study ATS/ERS/JRS/
ALAT
2011 SGRQ 182 85 65.6 79.7
Glaspole et al. [53] Australia 2017 Observational study NR NR SGRQ 422 67 71.3 81.0
Koyama et al. [135] Japan 2017 Prospective cohort study ATS/ERS/JRS/
ALAT
2011 Bartel Index 47 89 75.5 75.4














































Lee et al. [137] South Korea 2017 Prospective cohort study ATS/ERS/JRS/
ALAT
2011 SGRQ 112 84 70.0 85.0
Magnani et al. [35] Italy 2017 Prospective cohort study ATS/ERS/JRS/
ALAT
2011 PGWBI 18 45 66.5 62.4
Matsuda et al. [138] Japan 2017 Retrospective cohort study ATS/ERS/JRS/
ALAT
2011 SGRQ 121 82 66.8 81.1




106 85 67.1 81.9
Natalini et al. [140] USA 2017 Cross-sectional study ATS/ERS/JRS/
ALAT
2011 SF36 50 78 70.8 70.3




188 56 65.8 73.9




52 85 72.0 86.1
Swigris et al. [143] Multi-country 2017 RCT (TOMORROW-1) ATS/ERS 2000 SGRQ 426 75 65.1 81.3
Wapenaar et al. [65] Multi-country 2017 Prospective cohort study ATS/ERS 2000 SGRQ
KBILD
EQ5D
108 78 70.5 72.5
Atkins et al. [66] UK 2018 Prospective observational study ATS/ERS/JRS/
ALAT
2011 KBILD 39 69 75.1 82.7
Bacci et al. [144] USA 2018 Cross-sectional qualitative study and






30 60 67.7 70.2
Capparelli et al. [70] Argentina 2018 Cohort study- instrument validation ATS/ERS/JRS/
ALAT
2011 SGRQI 23 78 71.9 68.9
da Fontoura et al. [40] Brazil 2018 Retrospective cohort study NR SF36 31 60 57.1 49.0




87 62 70.1 84.21




273 79 70.2 67.0
Mavroudi et al. [147] Greece 2018 Case control study ATS/ERS 2000 SF36 19 58 69.8 75.6
Nishiyama et al. [148] Japan 2018 Prospective observational study ATS/ERS/JRS/
ALAT
2011 SGRQ 31 74 72.3 73.8
Nolan et al. [53] UK 2018 Prospective cohort study ATS/ERS/JRS/
ALAT
2011 KBILD 65 89 72.0 73.2
Raghu et al. [149] USA 2018 RCT (WRAP-IPF) ATS/ERS/JRS/
ALAT
2011 SGRQ 58 82 69.9 75.4




RAND36 92 73 75.0 78.0
Rosas et al. [151] USA 2018 RCT ATS/ERS/JRS/
ALAT
2011 SGRQ 58 81 67.6 71.1
Swigris et al. [152] Multi-country 2018 RCT (INPULSIS-1, INPULSIS-2) ATS/ERS 2000 SGRQ
EQ5D










































Szentes et al. [54] Germany 2018 Prospective observational study NR NR KBILD
EQ5D
268 86 63.2 77.4
Takeda et al. [153] Japan 2018 Prospective cohort study ATS/ERS/JRS/
ALAT
2015 COPD 25 84 74.4 80.6
Vancheri et al. [154] Multi-country 2018 RCT (INJOURNEY) ATS/ERS/JRS/
ALAT
2011 EQ5D 104 86 68.9 84.0




277 77 69.6 80.6
Bosi et al. [156] Italy 2019 Prospective observational study ATS/ERS/JRS/
ALAT
2011 SGRQ 47 76 68.7 75.5
Chehere et al. [157] France 2019 Prospective cohort study ATS/ERS 2001 SF36 19 75 65.0 75.0
Eken et al. [158] Turkey 2019 Cross-sectional study ATS/ERS/JRS/
ALAT
2011 SGRQ 40 78 65.5 86.6
Justice et al. [159] USA 2019 RCT ATS/ERS/JRS/
ALAT
2011 SGRQ 14 88 70.8 NR
Kalafatis et al. [69] Sweden 2019 Observational study ATS/ERS/JRS/
ALAT
2011 KBILD 348 72 72.0 70.2
Kimman et al. [57] Netherlands 2019 Prospective cohort study NR NR PESaM
EQ5D
188 76 69 NR
Kreuter et al. [55] Germany 2019 Observational study NR NR SGRQ
EQ5D
424 77 68.7 36.1
Nolan et al. [56] UK 2019 Prospective cohort study NR NR KBILD 209 61 70.0 71.9




20 70 58.3 NR





150 81 72.9 87.2
Ryerson et al. [160] Multi-country 2019 RCT (INPULSIS-1, INPULSIS-2) ATS/ERS 2000 SGRQ 1060 79 66.8 79.6
Sinha et al. [36] UK 2019 Prospective cohort study NR NR KBILD 57 33 62.0 80.0
Wallaert et al. [161] France 2019 Prospective cohort study ATS/ERS/JRS/
ALAT
2011 VSRQ 61 75 66.8 68.6
Witt et al. [162] Multi-country 2019 Prospective observational study ATS/ERS/JRS/
ALAT
2011 SF36 258 73 67.3 62.7
Xu et al. [163] China 2019 RCT (INPULSIS-1, INPULSIS-2) ATS/ERS 2000 SGRQ 101 54 64.3 80.8
Yuen et al. [164] USA 2019 RCT ATS/ERS/JRS/
ALAT
2011 SGRQ 20 65 69.8 66.0
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Janssen et al. [166] USA 2020 RCT ATS/ERS/JRS/
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Kreuter et al. [167] Multi-country 2020 RCT (INPULSIS-1, INPULSIS-2) ATS/ERS 2000 SGRQ 1061 79 66.8 79.6
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98 83 70.8 77.0
All means are calculated pooled means. ACE-IPF: Anti-Coagulant Effectiveness in Idiopathic Pulmonary Fibrosis; ATS/ERS: American Thoracic Society/European Respiratory Society; ATS/
ERS/JRS/ALAT: American Thoracic Society/European Respiratory Society/Japanese Respiratory Society/Latin American Thoracic Society; ATAQ-IPF: A Tool to Assess Quality of life in IPF;
BUILD: Bosentan Use in Interstitial Lung Disease; CQLQ: The Cough Quality of Life Questionnaire; CTS: Chinese Thoracic Society; EQ5D: EuroQol; FVC: Forced vital capacity; HUI2: Health
Utilities Index Mark 2; IPF: idiopathic pulmonary fibrosis; K-BILD: King’s Brief Interstitial Lung Disease; LCQ: Leicester Cough Questionnaire; NR: not reported; PANTHER Prednisone,
Azathioprine, and N-acetylcysteine in Participants With IPF; PESaM: Patient Experiences and Satisfaction with Medications Questionnaire; PGWBI: The Psychological General Well-Being
Index; PROMIS: Participant Reported Outcomes Measurement Information System; QoL-RIQ: Quality-of-Life for Respiratory Illness; RAND36: Research and Development 36 item health
survey; RCT: Randomised controlled trial; SF12: Short Form-12; SF36 Short Form-36; SGRQ: St George’s Questionnaire; SGRQI: IPF-specific version of the SGRQ; STEP-IPF: Sildenafil
Trial Of Exercise Performance In Idiopathic Pulmonary Fibrosis; VSRQ: Visual Simplified Respiratory Questionnaire; WHOQoL: WHO Quality of Life Questionnaire; WRAP-IPF: Treatment of

























supplementary material S9. Like the SGRQ, the domains related to mental wellness had better scores than
those related to physical wellness.
Once more, disease severity and age group influenced the pooled mean scores for both physical and
mental health domains. Thus, HRQoL deteriorated as the disease progressed in severity and worse HRQoL
was generally seen in the younger age groups. (figure 3b and 3c). This pattern is consistent with the results
of the SGRQ subgroup analysis. Similar to the SGRQ, there was little difference between the summary
scores for both physical and mental health domains in the subgroup analysis for study quality.
EQ5D
There were a limited number of studies with results for the EQ5D. Nine studies were used in the utility
analysis and 12 studies for the EQ VAS analysis. The pooled mean scores (95% CI) for the utility and EQ
VAS were 0.73 (0.68–0.79) and 65.66 (61.75–69.58), respectively.
The power of the subgroup analysis for EQ5D was limited as a result of the low number of studies
available (figure 4c)
KBILD
12 studies were used in the analysis for the KBILD. Pooled mean total score (95% CI) was 58.38 (55.26–
61.51).
The power of the subgroup analysis for KBILD was also limited as a result of the low number of studies
available. However, the total score for the KBILD was negatively impacted by disease severity, as there was
a decrease in the total score with increasing disease severity. The younger age group, 60–69 years, had a
worse score than the older age group, 70–79 years (figure 4d).
Sensitivity analysis and bias
Sensitivity analyses showed that there were no outliers (figure 5a and supplementary material S10-1).
To corroborate our results, we used a second method based on the sample size of the study (figure 5b
and supplementary material S10-2). The results again showed little change in the scores for all the
instruments except for the KBILD and SGRQ, which demonstrated a minimum score 5.9 and 4.4 points
less, respectively, than the calculated mean from the meta-analysis. This, however, is within the
minimal important difference for this instrument which is between 6–10 for KBILD and 5–8 for the
SGRQ [75, 76].
The trim and fill method yielded an asymmetrical funnel plot which can be attributed to high
between-study heterogeneity (figure 5c).
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FIGURE 3 Forest plots showing pooled means and subgroup analysis for St George’s Respiratory Questionnaire (SGRQ) and Short Form 36 (SF36).
QOL: quality of life.
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Discussion
To date this is the first systematic review with a meta-analysis statistically evaluating impacts on HRQoL in
IPF patients, and the patient reported outcome measures (PROM) used in IPF studies. Our results show
that, although studies have been published from the early 2000s, there has been an influx of research on
HRQoL in the last 4 years, and even more specifically since 2017. Furthermore, though disease-specific
instruments have been developed, there is still a predilection for the use of generic multi-attribute
instruments. The most frequently used instruments for measuring HRQoL were SGRQ, SF36, KBILD and
EQ5D. These instruments demonstrated that the impact of IPF is not restricted only to respiratory
Group/
Subgroup
EQ5D Visual analogue scalea) b) c)EQ5D Utility KBILD Total
Studies n QOL (95% CI)
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Subgroup Studies n QOL (95% CI)
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Subgroup Studies n QOL (95% CI)







































QOL (95% CI) QOL (95% CI)Utility (95% CI)






























FIGURE 4 Forest plots showing pooled means and sub-group analysis for EuroQoL (EQ5D) and King’s Brief Interstitial Lung Disease questionnaire
(KBILD). QOL: quality of life.
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FIGURE 5 Summary plots for sensitivity analyses and funnel plot for assessment of publication bias. QOL: quality of life; EQ5D: EuroQoL; SGRQ:
St George’s Respiratory Questionnaire; SF36: Short Form-36; KBILD: King’s Brief Interstitial Lung Disease questionnaire.
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limitations but to all aspects of life, including physical, emotional and social functioning; however, the
most affected aspect was the physical domain. HRQoL is further influenced by age and disease severity.
When compared with the general population and COPD patients with moderate disease, HRQoL is
substantially worse in people living with moderate IPF. Taken together, the data from this review extend
and update our previous knowledge and confirm that IPF markedly affects the HRQoL of people living
with the disease and that this can be measured quantitatively.
Our study demonstrated an increase in the number of studies in the past 4 to 5 years. This can be
attributed to the increase in studies which have used HRQoL as an outcome measure in clinical trials and
other studies [7]. Clinical trials continue to evaluate new drugs and interventions that may halt disease
progression and, as a result, extend life and improve quality of life. Currently there is no treatment to cure
IPF. In particular, in recent years, two new drugs, pirfenidone and nintedanib have been approved for the
treatment of IPF in many countries [7]. These have been shown to improve lung function and slow
progression of the disease in people with mild-to-moderate disease, but not to reverse or cure the disease
[128, 170]. Given this, there has been an emphasis and increase in research in the past few years to
ascertain optimal dosing, optimal timing of therapy and potential combination therapy using these two
drugs in addition to research for new therapies [171]. However, there is still some uncertainty as to the
utility of using HRQoL as an outcome measure for these studies [172]. In the first instance, there is debate
on the most appropriate instrument that should be used [173]. Although some of the most used
instruments such as the SGRQ and SF36 have been validated and deemed appropriate for measuring
HRQoL in people with IPF, there is still discussion on whether they are sensitive enough to measure
disease-specific deficits [8, 172]. Secondly, many of these instruments have not convincingly demonstrated
major changes in HRQoL in some of the most important clinical trials [8]. Lastly, there is still some
ambiguity on the how the side effects of the drugs under investigation influence the reporting of HRQoL
[172].
Our study showed that the three most-used instruments for measuring quality of life in IPF were SGRQ,
SF36, KBILD and EQ5D. Finding the appropriate instrument for measurement of HRQoL has been an
ongoing debate in the field of IPF [8]. Both the SGRQ and SF36 have been validated and have been shown
to have adequate psychometric properties to assess HRQoL in IPF [43, 143, 162] and have been used in
clinical trials to measure outcomes. Notwithstanding, consensus on whether they are sufficiently sensitive
to capture unique aspects of the disease is undecided [9]. Although this may be accurate, studies have
demonstrated that SGRQ and SF36 yield HRQoL scores that correspond to physiological or clinical
measures, showing low scores in the domains corresponding to disease-related deficiencies. PENG et al.
[88], NISHIYAMA et al. [79] and MARTINEZ et al. [43] were all able to demonstrate concurrence between
clinical and physiological measures and HRQoL measured by the SGRQ and SF36. Although this is
beyond the scope of this paper, these two instruments have also been proven to be sensitive enough to
identify minimally important changes in clinical status [76]. SWIGRIS et al. [76] demonstrated that both the
SGRQ and SF36 were able to detect small improvements or decline in clinical status of study subjects. For
the SF36, a change of 2–4 points was associated with changes in the clinical status, whereas with the
SGRQ, a change of 5–8 was associated with clinical status change [76]. According to these findings, we
can infer that these two instruments are suitable options for use in clinical trials where HRQoL is being
measured as an outcome, with the caveat that disease-specific deficiencies may not be captured.
Our study recorded a pooled mean utility of 0.73 (0.68–0.79). To put this into perspective, when we
compare this value to a similar cohort of the general population the utility values is 0.825 with a standard
error of 0.005 [[0] and with a similar cohort of persons with moderate COPD, the utility value is 0.74
(0.66–0.83) [174], signifying that persons with IPF generally have a poorer HRQoL. This is one of the
advantages of multi-attribute instruments like the EQ5D. When used in the assessment of HRQoL of
persons living with IPF they enable comparisons with other disease entities or other populations, and
allow the generation of health state utility values that can be utilised in the calculation of quality-adjusted
life years, an important measure used in reimbursement decision making and health economic evaluations
[175]. Despite this advantage, the EQ5D is not one of the instruments recommended for measuring
HRQoL for IPF as there is little evidence on its measurement properties in relation to IPF [10]. For this
reason, the instrument has been used in combination with other validated generic instruments or
disease-specific instruments in studies. Mapping of validated instruments to the EQ5D has also been an
option to generate data for economic evaluations. Although this has been done in many disease conditions
for the SF36, it has not been done for IPF. FREEMANTLE et al. [176], however, conducted a mapping of
SGRQ to the EQ5D in IPF patients, and SWIGRIS et al. [76] conducted a similar mapping exercise for the
SGRQ to the SF36. Given the continued research into optimal therapies and the need for economic
evaluation to assess the cost effectiveness of these for health systems, it may be appropriate at this point to
conduct validation studies for the EQ5D and, in addition, evaluate other multi-attribute instruments, to
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assess their suitability in comparison with the EQ5D, for assessing HRQoL in people with IPF. The
establishment of minimal inhibitory difference for IPF for these instruments is also important if they are
to be used in relation to clinical outcomes. These are significant issues and we will seek to address some of
these in our future work.
Our analysis of the KBILD, albeit limited by the number of studies, further confirmed that IPF had a
detrimental effect on HRQoL. The KBILD initially designed for ILD has shown tremendous promise for
assessing HRQoL in IPF, especially in capturing disease-specific deficits. One of the advantages of this
instrument is that it is simple enough to be used both in the research and clinical setting [177]. Validation
studies have shown that the instrument demonstrates high internal consistency, good validity, good
reliability and responsiveness [36, 56, 75, 177] in the assessment of HRQoL of IPF patients. In relation to
the responsiveness, recent research has also demonstrated that the instrument is sensitive enough to detect
MCIDs with scores as low as 2.9–4.9, which further supports the instruments suitability for use in IPF
research and clinical use [36]. Notwithstanding the successes of this instrument, longitudinal studies with
larger cohorts are needed; however, this can be quite challenging given the natural history of the disease
and short survival times. However registries such as the Swedish IPF registry are a good opportunity for
longitudinal validation as it makes use of this instrument [61].
Our review revealed that paradoxically very few studies used disease specific instruments. Psychometric
evaluation and validation studies have shown that these tools have considerable potential in capturing
disease-specific properties that influence HRQoL, compared with the generic instruments [36, 56, 74, 178].
The ATAQ-IPF and the SGRQ-I are two of the older disease specific instruments which have been
validated, but newer instruments continue to show potential. The Living with IPF questionnaire (L-IPF)
[179], an updated and improved version of the ATAQ-IPF, based on patient feedback of the former
instrument, is currently under validation [180]. The Patient Reported Outcome Measure (IPF-PROM),
which was recently validated, has demonstrated good reliability, validity and correlates strongly with other
instruments such as the SGRQ and moderately with FVC [181]. This instrument is currently being
evaluated for its responsiveness. Disease specific patient reported experience measure questionnaires
(PREMs) are a novel opportunity to capture information that will complement PROMs. The IPF-PREM
[182] was developed to complement current PROMs and capture information on patient experience with
service delivery and IPF-specific medication in the UK. The Patient Experiences and Satisfaction with
Medications (PESaM) Questionnaire [183] captures information patient experiences with IPF-specific
medication. Both are still undergoing validation but will offer insight into areas that do affect patient
outcomes. The prospects that all of these instruments offer are quite encouraging for the future
monitoring of patients with IPF; however, further research beyond validation and their responsiveness is
needed to assess their suitability in the clinical setting to monitor patients.
Our results demonstrate that having IPF affects all measured aspects of HRQoL with the physical health
domains being most affected. Both the SGRQ and the SF36 identified worse deficits in the physical health
and functioning domains compared with psychosocial domains. Given the natural history of the disease
and the main symptoms, dyspnoea, cough and fatigue [3], the larger deficit in the physical health domains
is expected. Albeit that the severity of these symptoms can be measured objectively through diagnostic
tests, patient perspectives on how it affects their daily life and coping mechanisms provides a realistic life
perspective that should be used to guide patient management and to assess new therapeutic outcomes of
ongoing and future research [8]. Both instruments also showed deficits in domains related to emotional
functioning, consistent with available evidence that people with chronic diseases are abnormally
predisposed to anxiety and depression [8]. Dyspnoea and coughing in IPF have been directly linked to
anxiety and the poor prognosis of the disease has been linked to depression [8].
The subgroup analysis of different age groups using the SGRQ, SF36 and KBILD showed worse pooled
mean scores in younger age groups, irrespective of disease severity. Although this was not expected,
further review of the literature revealed a population-based study in the USA of people with chronic
diseases, which demonstrated similar results. The study included 201711 people with chronic diseases and
demonstrated that younger age group reported poorer quality of life [184]. One plausible explanation is
that younger age groups may still be employed and more socially active so the limitations imposed by
chronic disease may be more restrictively impactive than for older persons. However, this outcome was not
seen with the EQ5D. Potentially, the EQ5D may not be sensitive enough to detect disease-specific deficits
[54] and, additionally, the instrument has not been validated for ILD and, more specifically, IPF [54].
Secondly, the number of studies used in the synthesis for the EQ5D is small, and as a result of this, there
is potential for inaccurate estimation of the in-between study variance and resultant pooled means during
the analysis [185]. Lastly, it is important to note that patterns that may be seen in the individual studies
may not necessarily translate when the studies are aggregated in a meta-analysis and this may be as a
result of aggregation bias [186]. The subgroup analysis for all instruments for disease severity confirmed
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that disease severity itself had a negative impact on HRQoL. This was demonstrated in particular in the
studies by GLASPOLE et al. [53] and LEONARD et al. [187], which compared gender and lung physiology
(GAP) stages with quality-of-life measures. Both studies established a correlation between a higher GAP
stage and worse HRQoL scores.
There wasn’t clear evidence of publication bias; however, it should be noted that when there is a high level
of between-study heterogeneity the bias detection tests are less reliable [29]. Nevertheless, the influence of
individual studies on the overall meta-analysis for each instrument did not show significant outliers
signifying that the results of the analyses were robust and not affected by the bias. Additionally, subgroup
analysis was performed to account for the influence of the demographic and quality of the study
variability in the studies. Lastly the study excluded abstracts which may introduce bias due to a lack of
peer review.
This study improves on previously published reviews [11, 12] as it contains twice as many studies and was
able to include a meta-analysis for the first time. There were, however, some limitations to the study. First,
HRQoL scores in most studies did not consider comorbidities which are frequent in the age range under
study. Although the exact mechanism of how comorbidities affect the disease process in IPF is still
unclear, studies have demonstrated that improving the management of comorbidities improves quality of
life and survival in patients with IPF [8, 188, 189]. Secondly, the clinical standards for diagnosis of IPF
varied, with some studies using standards that were not in accordance with international consensus [46–
48] and in cases where international consensus standards were used, the standards for diagnosis varied
since there were updates to the standards in 2000, 2011, 2015 and in 2018. In addition to the
aforementioned, the exclusion of studies on the basis of language may introduce some bias in the analysis.
The consensus on this, however, is that the effect may be minimal [28]. Lastly, we omitted grey literature
from our study which may increase publication bias in the analysis [190]. There is, however, a lack of
consensus on the effect of the inclusion or exclusion of grey literature on publication bias in systematic
reviews and meta-analyses [191].
In conclusion, this study extends previous knowledge by showing that IPF has detrimental effects on
HRQoL of people living with the disease and the domain most affected is that measuring physical
functioning. Given the demonstrable poor quality of life in addition to the already well-known poor
survival time related to IPF patient-management strategies should not only be focussed on clinical
outcomes. Emphasis should also be placed on strategies to improve quality of life of people living with the
disease with a more holistic approach to care.
Conclusion
This study set out to evaluate HRQoL in IPF and how it is measured. Our review demonstrated that
HRQoL is markedly affected by IPF and that the most affected part of life is that related to physical
functioning. Furthermore, our review revealed that there are a diverse number of instruments used to
measure HRQoL in people with IPF, many of which are not disease specific instruments although they
have been validated for the disease. In view of this and emerging research to find optimal therapies to treat
the disease, a standardised approach to measure HRQoL is needed. This will allow for a more harmonised
approach to comparisons across trials and different populations.
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